Latest Intelligence on Pharmaceuticals in United States

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

ZymoGenetics: early hope for late-stage disease

ZymoGenetics has reported positive results from its phase Ia study of IL-21 in patients with metastatic melanoma and metastatic renal cell carcinoma. This announcement warrants further studies of IL-21 in these indications, which is welcome news for ZymoGenetics and development partner Novo Nordisk. However, competition is already on the horizon, in the form of Bayer/Onyx' Nexavar.

Published By Datamonitor
15 Nov 2005
Expert View
Expert View

Zelboraf's approval demonstrates a significant shift toward personalized cancer therapy

The FDA has approved Zelboraf and Roche's companion diagnostic test for BRAF V600E mutation-positive metastatic melanoma. The joint approval is the first example of co-development and demonstrates the movement toward personalized cancer therapy, and Zelboraf's impressive efficacy data and the availability of a test will ensure rapid uptake.

Published By Datamonitor
18 Aug 2011
CommentWire
CommentWire

Xanthus: more hurdles to clear for Symadex

Xanthus Life Sciences has begun dosing patients in a phase II trial of Symadex in recurrent colorectal cancer. While this is clearly a positive step in Symandex' development, the drug candidate still has phase III trials to contend with and, even if Symandex proves fit for launch here, Xanthus will need to find a marketing partner to help it achieve commercial success in the tough cancer market.

Published By Datamonitor
17 Jan 2006
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Wyeth: breast cancer prospects receive a blow

Wyeth has discontinued a phase III trial of temsirolimus plus letrozole in metastatic post-menopausal hormone-receptor positive breast cancer. This is a significant blow for the company due to the loss of earnings potential in the congested but lucrative breast cancer market. However, temsirolimus remains under development for a number of other tumors, and so hope for the drug candidate remains.

Published By Datamonitor
23 Mar 2006
CommentWire
CommentWire

Wyeth/MedImmune: the end of the road for FluMist venture

Following poor first-year performance, Wyeth [WYE] and MedImmune [MEDI] have announced the dissolution of their FluMist partnership. If MedImmune is to achieve success with this product alone, it may need to rethink its premium pricing strategy.

Published By Datamonitor
28 Apr 2004
CommentWire
CommentWire

Wyeth/MedImmune: second generation vaccine

Wyeth [WYE] and MedImmune's [MEDI] FluMist failed to secure indications for use in key target groups for influenza vaccine in the US. Recently released results suggest that their second generation product may enable the two companies to capitalize on more conventional influenza vaccine sectors.

Published By Datamonitor
15 Oct 2003
CommentWire
CommentWire

Wrigley: Viagra gum raises expectations

If Wrigley [WWY] is to bring its Viagra gum to market before 2011 it will need to negotiate hard with Pfizer [PFE], which holds the Viagra patent until then. If the product does come to market, demand will undoubtedly be high. If a success, the technology of implanting drugs in gum could increase in popularity and potentially be used for more valuable healthcare applications.<BR />

Published By Datamonitor
16 Jun 2003
Expert View
Expert View

Will contraceptive patches challenge the pill?

Although the contraceptive pill has been hugely successful, remembering to take it every day can be a problem. Alternative delivery methods such as implants and injections, meanwhile, have proved unpopular. The contraceptive patch could fill the middle ground, potentially cutting unwanted pregnancies - but will it? Datamonitor women's health analyst Jane Richardson cuts through the hype...

Published By Datamonitor
28 Mar 2002
Expert View
Expert View

Vertex: next-generation hepatitis drugs within reach

Vertex has launched a major phase II clinical trial to test a new hepatitis C drug candidate, with a second trial scheduled to begin in June. This is a significant advance in the development of much-needed treatments for hepatitis C. By drawing parallels with similar HIV treatments, Datamonitor's Morris Paterson outlines the pitfalls and prospects for this new drug.

Published By Datamonitor
24 May 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.